Mariprax (Pramipexole Dihydrochloride Monohydrate)

Mariprax (pramipexole) acts on dopaminergic pathways to treat movement‑related disorders.

• Parkinson's disease: improves motor function and reduces rigidity and tremor in patients with idiopathic Parkinson's disease.
• Restless legs syndrome: decreases the frequency and severity of uncomfortable leg sensations and urges to move during periods of rest.

• Pramipexole is a selective agonist at dopamine D2 and D3 receptors. By binding to these receptors, it mimics dopamine activity, enhancing dopaminergic neurotransmission in the basal ganglia and other brain regions involved in motor control and sensory perception, thereby mitigating the motor deficits of Parkinson's disease and the sensory disturbances of restless legs syndrome.

Pramipexole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Somnolence: increased sleepiness or fatigue.
• Constipation: reduced bowel movements.
• Headache: mild to moderate head pain.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Impulse control disorders: compulsive gambling, shopping, or eating.
• Hallucinations: visual or auditory perceptions without external stimulus.
• Orthostatic hypotension: sudden drop in blood pressure upon standing.
• Sudden onset of sleep: unexpected episodes of sleep during wakeful activities.
• Severe allergic reactions: rash, swelling, or difficulty breathing.
• Neuroleptic malignant‑like syndrome: high fever, muscle rigidity, and autonomic instability.

When prescribing Mariprax, clinicians should consider several safety factors.

• Renal impairment: adjust dose and monitor renal function.
• Elderly patients: start with low dose and monitor for orthostatic hypotension.
• Psychiatric history: monitor for hallucinations or impulse control disorders.
• Pregnancy and breastfeeding: use only if benefits outweigh risks.
• Concomitant MAO‑B inhibitors: avoid combination due to risk of hypertensive crisis.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Pramipexole can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• MAO‑B inhibitors: risk of hypertensive crisis.
• Antipsychotics (dopamine antagonists): may reduce therapeutic effect.
• CYP2D6 inhibitors (e.g., quinidine): increase plasma levels.

Moderate Interactions (Monitor Closely)

• Alcohol: may enhance central nervous system depression.
• Antihypertensives: additive effect on blood pressure.
• Other dopamine agonists: increased risk of side effects.